

Peer Reviewed



# Anemia in a Cat— Can You Identify Why?

An adult spayed mixed-breed cat presented with ataxia and chronic left hindlimb weakness.

## HISTORY

In addition to hindlimb weakness and ataxia, muscle atrophy was evident and the cat had a several-month history of listlessness. Cythioate (Proban) had been previously used for flea control, but not in the 2 months before presentation. The cat was referred to University of Florida Small Animal Hospital for neurologic examination.

## EXAMINATION

On initial examination, the cat had pale mucous membranes, tachypnea, and a rectal temperature of 104°F. Orthopedic examination revealed a probable ruptured anterior cruciate ligament in the left hindlimb. Neurologic examination revealed signs of multifocal disease, including diminished motor control and sensation in the tail, decreased superficial sensation on the right side of the body, and hyperactive anal reflex in addition to ataxia.

## DIAGNOSTIC FINDINGS

The cat had macrocytic normochromic anemia (Table). The plasma appeared colorless on whole blood centrifugation in a microhematocrit tube. Erythrocyte morphology included moderate anisocytosis without polychromasia (Figure 1). A platelet count was not done, but the platelet numbers

appeared to be decreased (estimated  $90 \times 10^3/\mu\text{L}$ ) on the stained blood film. Macroplatelets were often observed (Figures 1 and 2), along with lymphopenia and monocytosis. Occasional hypersegmented neutrophils and rare giant hypersegmented neutrophils were seen (Figures 1 and 3).

The serum biochemical panel was unremarkable. Because acetylcholinesterase activity was normal, organophosphate toxicity was considered unlikely.




### Findings Consistent with Macrocytic Normochromic Anemia

Parameter	Patient	Reference Interval
Hematocrit (%)	16	34–51
MCV (fL)	53	42–52
MCHC (g/dL)	32	30–33
Neutrophils ( $\times 10^3/\mu\text{L}$ )	8.9	2.3–9.8
Lymphocytes ( $\times 10^3/\mu\text{L}$ )	0.5	0.9–5.5
Monocytes ( $\times 10^3/\mu\text{L}$ )	2.3	0–0.8


MCV = mean cell volume, MCHC = mean cell hemoglobin concentration



**1** Giant hypersegmented neutrophil (left), normal-sized neutrophil (center), and macroplatelet (top right) in blood from a cat. Several macrocytic erythrocytes are also present. (Wright-Giemsa stain)



**2** Macroplatelet (center) in blood from a cat. The granules appear as a pseudonucleus in the center of the platelet. (Wright-Giemsa stain)



**3** Hypersegmented neutrophil (bottom center) and macrocytic erythrocyte (top left) in blood from a cat. (Wright-Giemsa stain)

## ? Ask Yourself...

1. Is the anemia regenerative or nonregenerative?
2. What is the general mechanism responsible for producing the anemia?
3. What additional tests might you conduct to evaluate the anemia?

CONTINUES

## EASOTIC®

Otic suspension

(hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Anti-inflammatory, antifungal, and antibacterial

For Otic Use in Dogs Only

### CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**BRIEF SUMMARY:** Please consult package insert for complete product information.

### INDICATIONS

EASOTIC® suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

### CONTRAINDICATIONS

Do not use in dogs with known tympanic membrane perforation.

EASOTIC® suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.

### WARNINGS

**Human Warnings:** Not for use in humans. Keep this and all drugs out of reach of children.

Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product.

**Animal Warnings:** As a class, aminoglycoside antibiotics are associated with ototoxicity, vestibular dysfunction and renal toxicity. The use of EASOTIC® suspension in a dog with a damaged tympanic membrane can result in damage to the structures of the ear associated with hearing and balance or in transmission of the infection to the middle or inner ear. Immediately discontinue use of EASOTIC® suspension if hearing loss or signs of vestibular dysfunction are observed during treatment (see **ADVERSE REACTIONS**).

### PRECAUTIONS

Do not administer orally.

Concurrent administration of potentially ototoxic drugs should be avoided.

Use with caution in dogs with impaired hepatic or renal function (see **ANIMAL SAFETY**).

Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **ANIMAL SAFETY**).

The safe use of EASOTIC® suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

**ADVERSE REACTIONS** In a field study conducted in the United States, there were no adverse reactions reported in 145 dogs administered EASOTIC® suspension.

In foreign market experience, reports of hearing loss and application site erythema have been received. In most reported cases, the hearing loss and erythema were transient and resolved with discontinuation of EASOTIC® suspension.

To report suspected adverse drug events, or for technical assistance contact Virbac at 800-338-3659.

### ANIMAL SAFETY

Aural administration of EASOTIC® suspension to 12 week old Beagle dogs at 1, 3, and 5 times the recommended dose (1 mL/ear/day) for 15 days (three times the treatment length) was associated with alterations of the hypothalamic-pituitary-adrenal axis as evidenced by the ACTH stimulation results. Other findings considered to be related to treatment include the development of aural hyperemia; the presence of renal tubular crystals and possibly renal tubular basophilia and atrophy; elevated liver weights; the development of otitis externa and media; and elevations in alanine aminotransferase, alkaline phosphatase, total protein, albumin, and cholesterol levels.

**STORAGE INFORMATION:** Store at temperatures between 20° C-25° C (68° F-77° F), with excursions permitted between 15° C-30° C (59° F-86° F).

**HOW SUPPLIED:** EASOTIC® suspension is supplied in a polyethylene canister, with a soft applicator canula.

Distributed by:

Virbac AH, Inc.  
Fort Worth, TX  
76137 USA

NADA 141-330, Approved by FDA.

© 2011 Virbac AH, Inc.

All Rights Reserved. Rev 8/2011



## DIAGNOSIS: Myelodysplastic Syndrome (MDS)

### FINDINGS & FOLLOW-UP TESTING

The cat's anemia appeared nonregenerative based on lack of polychromasia in the stained blood film. However, a reticulocyte count was not done to rule out the presence of increased punctate reticulocytes. Punctate reticulocytes, in contrast to aggregate reticulocytes, do not appear polychromatophilic in stained blood films. However, the clinician would expect increased numbers of aggregate reticulocytes to be released from the bone marrow in response to a hematocrit of 16%, assuming the anemia was present for at least 3 to 4 days (ie, the time required for the formation of aggregate reticulocytes in bone marrow).

Based on the history of listlessness for several months, anemia had likely been present for at least several weeks to months. The mean cell volume was slightly increased, indicating that increased anisocytosis may have resulted from macrocytic erythrocytes in the blood. Anisocytosis may be present in both regenerative and nonregenerative anemia. In this cat, nonregenerative anemia may have resulted from decreased erythrocyte production. Macrocytic platelets may be released in response to peripheral platelet utilization or destruction but have also been reported in animals with dysplastic megakaryocytopoiesis.

Lymphopenia, eosinopenia, and monocytosis may have resulted from endogenous glucocorticoid release. Neutrophilia is also expected in response to glucocorticoids; however, the neutrophil count tends to normalize with chronic glucocorticoid exposure. The presence of occasional hypersegmented and rare giant neutrophils in this patient suggested

that dysgranulopoiesis may have been present in the bone marrow.

Macrocytic nonregenerative anemia is common in FeLV-infected cats, and the FeLV test was positive in this cat. Nonregenerative anemia with thrombocytopenia and/or leukopenia may also occur with feline immunodeficiency virus (FIV) infection; however, this test was not conducted and a combined infection cannot be ruled out. However, once MDS was diagnosed, the case workup, including more sophisticated neurologic examination, was curtailed.


Because the presence of nonregenerative anemia, thrombocytopenia, and neutrophilic morphologic abnormalities suggested a bone marrow disorder, a bone marrow aspirate was obtained.

### ASPIRATION FINDINGS


The bone marrow was of normal or increased cellularity (Figure 4). Megakaryocytes were present in normal numbers, but abnormal dwarf megakaryocytes were also observed (Figure 5).

Both the erythroid and myeloid series were complete, but both series had morphologic abnormalities. Erythroid cells were often megaloblastic (Figure 6), with a moderate increase in immature cell types. The myeloid series had an increased proportion of cells in the proliferating pool (ie, myeloblasts, promyelocytes, myelocytes) relative to cells in the maturation and storage pool (ie, metamyelocytes, bands, mature neutrophils). Myeloblasts accounted for less than 5% of all nucleated cells.

CONTINUES



Cellular bone marrow aspirate smear from a cat with a left shift in the granulocytic series, increased mitotic figures, and megaloblastic erythroid precursors. (Wright-Giemsa stain)



Dwarf megakaryocyte (center) and megaloblastic erythroid precursor (top right) in a bone marrow aspirate smear from a cat. (Wright-Giemsa stain)




### Did You Answer...

1. Nonregenerative
2. Decreased erythrocyte production
3. FeLV/FIV tests and bone marrow biopsy

MDS = myelodysplastic syndrome








6

Three megaloblastic erythroid precursors (**across top half of image**) and 2 mitotic neutrophil precursors in a bone marrow aspirate smear from a cat. (Wright-Giemsa stain)



7

Three mitotic neutrophil precursors in a bone marrow aspirate smear from a cat. One large neutrophilic precursor (**left**) contains 4 mitotic figures. (Wright-Giemsa stain)

Mitotic granulocytic cells were increased, and occasional giant neutrophilic cells and abnormal mitotic figures were recognized (**Figure 7**). The myeloid-to-erythroid (M:E) ratio was 1.7 (range, 1.2–2.2).

## DISCUSSION

### Myelodysplasia

The term *myelodysplastic syndrome* is generally used as a synonym for primary myelodysplasia. MDS consists of a heterogeneous group of neoplastic disorders that are characterized by peripheral cytopenias, especially nonregenerative anemia and thrombocytopenia, with normal to hypercellular, dysplastic-appearing bone marrow. This ineffective hematopoiesis results from defective maturation and extensive apoptosis (physiologic cell death) of hematopoietic cells.

As with MDS in humans, a clonal proliferation of hematopoietic cells has been identified in two-thirds of cats with MDS, suggesting that MDS may be considered a preleukemic state for acute myeloid leukemia (AML) in cats. FeLV (and probably FIV) infections can produce MDS in cats, although some cats with

MDS may have negative test results for these viruses.

As observed in this case, evidence of dyserythropoiesis, dysgranulopoiesis, and/or dysmegakaryocytopoiesis is present in the marrow of animals with MDS. Additional abnormalities may include: nonregenerative anemia with erythrocyte macrocytosis, anisocytosis, and/or poikilocytosis; nucleated erythrocytes (metarubricytosis) out of proportion to the number of reticulocytes present; nucleated erythrocytes with lobulated or fragmented nuclei; thrombocytopenia; and large bizarre platelets, immature granulocytes, and abnormal granulocyte morphology.

### Types of Myelodysplastic Syndrome

MDS has been classified into 3 subtypes in animals: MDS with erythroid predominance in the bone marrow (M:E ratio <1) may be classified as *MDS-erythroid* (MDS-Er). Cases with refractory anemia and an M:E ratio >1, with or without other refractory cytopenias, may be described as *MDS-refractory cytopenia* (MDS-RC). Myeloblasts account for less than 5% of all nucleated cells in this subtype. When

myeloblasts are increased (5%–19% of bone marrow nucleated cells), the term *MDS-excess blasts* (MDS-EB) may be used.

This cat can be classified as MDS-RC because the M:E ratio was >1.0 and myeloblasts did not exceed 5% of all nucleated cells. Cats with MDS may subsequently develop AML, and FeLV-positive cats with MDS have reportedly developed lymphoid neoplasms.

MDS must be differentiated from secondary myelodysplasia, which may be associated with immune-mediated disorders (immune-mediated hemolytic anemia, immune-mediated thrombocytopenia), lymphoid neoplasms, myelofibrosis, drugs that interfere with DNA synthesis, heavy metal toxicity, certain antibiotics, and anticonvulsant drugs. Once the client learned that the cat was FeLV positive with MDS, the decision was not to pursue further diagnostic evaluation for ataxia. The cat was released on palliative therapy and lost to follow-up.

See **Aids & Resources**, back page, for references & suggested reading.